SCHEMBL2998438

SCHEMBL2998438

CCC(=C(C(=O)O)C(=O)c1cccc(I)c1)N(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 1/20 0.40
HDAC2 Q92769 1/20 0.40
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
MTOR P42345 3/20 0.36
TP53BP1 Q12888 1/20 0.36
CES2 O00748 1/20 0.36
CES1 P23141 1/20 0.36
CTSL P07711 1/20 0.35
CTSS P25774 1/20 0.35
GRM5 P41594 1/20 0.35
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
MDM2 Q00987 1/20 0.32
SIGMAR1 Q99720 1/20 0.32
EGFR P00533 2/20 0.32
SCN2A Q99250 1/20 0.32
F2 P00734 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2998436 1.00 HDAC1 (0.40) HDAC1HDAC2SLC6A2SLC6A4SLC6A3
SCHEMBL1012189 0.84 CES2 (0.52) CES2CES1KMT2AEGFRHPGD
SCHEMBL1012187 0.84 CES2 (0.52) CES2CES1KMT2AEGFRHPGD
SCHEMBL29875488 0.73 MTOR (0.44) HDAC1HDAC2MTORTP53BP1CES2
SCHEMBL1931609 0.72 CES2 (0.47) CES2CES1TDP1
SCHEMBL18079795 0.71 CES2 (0.54) HDAC1HDAC2SLC6A2SLC6A4SLC6A3
SCHEMBL2086375 0.70 ERN1 (0.46) HDAC1HDAC2MTORTP53BP1CTSL
SCHEMBL2209426 0.70 HDAC1 (0.51) HDAC1HDAC2SLC6A2SLC6A4SLC6A3
SCHEMBL1430973 0.70 MTOR (0.38) HDAC1HDAC2MTORTP53BP1CTSL
SCHEMBL1429806 0.70 MTOR (0.38) HDAC1HDAC2MTORTP53BP1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8283361-B2 Heterocyclic urea derivatives and methods of use thereof ASTRAZENECA AB (SE) 2012-10-09 US disclosed
US-20100190745-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB (SE) 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190745-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF UROD, UMPS, SLC14A1 HDAC1 1346/4885HDAC2 2097/4885SLC6A2 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.